articleThe LancetOct 1, 2005Closed access

Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial

University of Göttingen · University Hospital of Zurich · +6 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

1,042
total citations
FWCI
18.23
Percentile
100%
References
33
Citations per year

Authors

9

Topics & keywords

Keywords
  • Infliximab
  • Psoriasis
  • Medicine
  • Psoriasis Area and Severity Index
  • Placebo
  • Internal medicine
  • Gastroenterology
  • Clinical endpoint
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.